Merck & Co. Stock News

The premise makes enough basic sense -- dividend income is good, so more dividend income is better. Therefore, if you want dividend income, make a point of buying higher-yielding stocks.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average revenue growth compared to J&J's modest 4%, and Merck's operating cash flow margins are a healthier 33% versus J&J's 28%.

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delive...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.

Even pros can't beat the market. Forecasts fail, fees pile up, and short-term thinking hurts returns. So I stick to quality dividend stocks. I found two high-conviction dividend stocks that the market is underpricing. Both offer strong income and long-term upside if my thesis plays out. They aren't perfect, but that's where the opportunity lies. I believe the market's pessimism is overdone, and...